Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rotigotine transdermal - UCB

Next Previous
Drug Profile

Rotigotine transdermal - UCB

Alternative Names: Leganto; N-0437; N-0923; Neupro; Neupro Patch; Nubrenza; Rotigotine PR2.1.1; Rotigotine PR2.2.1; SPM-962

Latest Information Update: 04 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aderis Pharmaceuticals
  • Developer Abbott Laboratories; Andromaco; Otsuka Pharmaceutical; UCB
  • Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome
  • Discontinued Fibromyalgia

Most Recent Events

  • 04 Jan 2024 No development reported - Phase-III for Restless legs syndrome (In adolescents) in USA (Transdermal) (NCT03728933) (UCB pipeline; January 2024)
  • 01 Mar 2023 BioNxt Solutions plans a clinical trial for Parkinson's disease in Europe (Transdermal, Patch) in the second quarter of 2023
  • 14 Apr 2021 Discontinued - Phase-II for Parkinson's disease in European Union (Intranasal) (UCB pipeline, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top